Precision Biosciences vs Editas Medicine
Editas Medicine is the larger business, with $40.5m of revenue in fiscal 2025 against $34.3m for Precision Biosciences (1.2 times as much). Editas Medicine grew faster (25.4% against -50.1%). Precision Biosciences kept more of each dollar of sales as profit: a net margin of -133.4% against -395.0%. Precision Biosciences carries less debt relative to equity (0.0% against 214.8%).
| Latest fiscal year | Precision BiosciencesDTIL, 2025 | Editas MedicineEDIT, 2025 |
|---|---|---|
| Revenue | $34.3m | $40.5m |
| Revenue growth | -50.1% | 25.4% |
| Net income | −$45.7m | −$160m |
| Operating margin | -152.2% | -394.9% |
| Net margin | -133.4% | -395.0% |
| Return on equity | -61.5% | -198.1% |
| Free cash flow | −$65.9m | −$166m |
| Cash | $111m | $147m |
| Total debt | $0 | $58.6m |
| Debt to equity | 0.0% | 214.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 68 | 87 |
| Market value | $184m | $252m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 8 (Weak) |
| Insider trades, 12 months | 6 buys, 11 sales | 0 buys, 14 sales |